Home/Filings/4/0001213900-25-100376
4//SEC Filing

STROME MARK E 4

Accession 0001213900-25-100376

CIK 0001101026other

Filed

Oct 19, 8:00 PM ET

Accepted

Oct 20, 4:19 PM ET

Size

12.2 KB

Accession

0001213900-25-100376

Insider Transaction Report

Form 4
Period: 2025-10-13
STROME MARK E
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-13$12.34/sh+20,259$249,996452,942 total(indirect: By entity)
  • Purchase

    Common Stock Purchase Warrant

    2025-10-13+2,02543,071 total(indirect: By entity)
    Exercise: $12.34From: 2025-10-13Exp: 2030-10-12Common Stock (2,025 underlying)
Transactions
  • Purchase

    Common Stock Purchase Warrant

    2025-10-13+2,02543,071 total(indirect: By entity)
    Exercise: $12.34From: 2025-10-13Exp: 2030-10-12Common Stock (2,025 underlying)
  • Purchase

    Common Stock

    2025-10-13$12.34/sh+20,259$249,996452,942 total(indirect: By entity)
Transactions
  • Purchase

    Common Stock

    2025-10-13$12.34/sh+20,259$249,996452,942 total(indirect: By entity)
  • Purchase

    Common Stock Purchase Warrant

    2025-10-13+2,02543,071 total(indirect: By entity)
    Exercise: $12.34From: 2025-10-13Exp: 2030-10-12Common Stock (2,025 underlying)
Footnotes (3)
  • [F1]The reported securities are owned directly by Strome Mezzanine Fund II, LP ("SMF II"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer.
  • [F2]Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the "Reporting Persons") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act").
  • [F3]Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.

Documents

1 file

Issuer

Zivo Bioscience, Inc.

CIK 0001101026

Entity typeother

Related Parties

1
  • filerCIK 0000919484

Filing Metadata

Form type
4
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:19 PM ET
Size
12.2 KB